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two Gianturco Z stents (Cook, Inc, Bloomington, Ind).
An Excluder self-expandable thoracic graft (WL Gore,
Flagstaff, Ariz) was used in the last three cases as part of a
single-center investigative device exemption for treatment
of thoracic aortic diseases. Devices were selected from hos-
pital stocks on the basis of measurements derived from
preoperative computed tomography (CT) scans and aor-
tograms.
The procedures were performed with the patients
under general anesthesia by surgeons in a dedicated vascu-
lar operative suite with complete fluoroscopic and angio-
graphic capabilities. All patients were given a single
intravenous dose of an antibiotic before surgery.
Intravascular access was obtained in both groins through
the common femoral artery and through the left brachial
artery. The common femoral artery determined to have
the least amount of occlusive disease was selected for
deployment and exposed. The patients were given 5000
units of intravenous heparin for anticoagulation.
Arteriographic 5F pigtail catheters were placed in the
common femoral artery and brachial artery. Aortography
and intravascular ultrasonography were performed to mea-
sure the dimensions of the thoracic aorta and distances
from the brachiocephalic and visceral vessels. Trans-
esophageal echocardiography (TEE) was used to delineate
the exact position of the fistula. If severe atherosclerotic
disease within the external iliac arteries prevented the pas-
sage of the delivery sheath into the aorta, then a retroperi-
toneal incision was made, and a Dacron graft conduit was
attached to the right common iliac artery for device deliv-
ery. A 24F sheath (Keller Timerman Sheath; Cook, Inc)
was inserted through the common femoral artery over a
stiff 0.035 Amplatz guide wire (Boston Scientific-
Meditech, Watertown, Mass) to the level of the thoracic
aorta. The device was inserted into the sheath. Temporary
Aortobronchial fistula (ABF) is a rare, potentially life-
threatening complication of thoracic aortic replacement
surgery. Often seen with substantial hemoptysis, its pres-
ence mandates urgent repair. Conventional open surgical
correction involves thoracotomy and carries significant
morbidity because of the difficulties of operative dissection
associated with reoperative surgery.1-3 The patients often
have other severe comorbidities and may have rather poor
health. These physiological stresses can be complicated by
active hemorrhage and pulmonary compromise. Further-
more, secondary graft infection, prolonged ventilatory
compromise, paralysis, kidney failure, and cardiac events
are significant potential complications of traditional open
repair.1-5 Endovascular technology as an alternative ther-
apy for ABF has been previously reported.6-9 We present
the successful treatment of four patients with ABFs by
endoluminal stent grafting.
METHODS
The records of all patients treated for ABF with endo-
luminal stent grafting at our institution were reviewed. All
patients gave written consent to endoluminal stent of the
thoracic aorta and intraoperative studies to evaluate and
exclude the fistula in accordance with techniques approved
by our institutional review board. The device used in the
first case, before the availability of commercially developed
grafts, was a composite of woven polyester graft sutured to
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Objective: To describe our experience with endoluminal stent graft repair of aortobronchial fistulas.
Methods: We reviewed the records of patients treated with endoluminal stent grafting of aortobronchial fistulas at a pri-
vate teaching hospital. All patients underwent the following diagnostic studies: computed tomography, angiography,
bronchoscopy, and transesophageal echocardiography. With standard endovascular techniques, two different devices
were implanted.
Results: Between March 1997 and October 2000, we treated four patients with postsurgical fistulas. The patients were
diagnosed with hemoptysis between 3 and 23 years after aortic replacement grafting for thoracic aneurysms. Diagnostic
studies varied in their ability to find the fistula. Transesophageal echocardiography most reliably demonstrated the fis-
tula in the patients. All were successfully treated by exclusion with endoluminal stent grafting. The patients had no
complications and no further episodes of hemoptysis.
Conclusion: Endoluminal stent grafting of aortobronchial fistulas is feasible and may become the preferred method of
management in patients at high risk. (J Vasc Surg 2002;35:387-91.)
hypotension was induced with nitroglycerin. The device
was deployed under fluroscopic and TEE guidance at the
designated landing zone. Postdeployment balloon dilation
was performed only if completion angiography demon-
strated an endoleak. Completion arteriography and TEE
were performed to assess accurate placement. The patients
were kept in the intensive care unit overnight. Post-
operative CT scanning of the chest was performed the
next day. The patients were discharged from the hospital
when they were ambulatory.
RESULTS
Between March 1997 and October 2000, we treated
four patients with aortobronchial fistulas by use of endo-
luminal stent grafts (Table I). All patients had previously
undergone thoracic aortic aneurysm repair with graft
interposition from 3 to 23 years before onset of hemopty-
sis. All patients experienced some degree of hemoptysis,
ranging from intermittent bloody expectoration to mas-
sive hemorrhage, resulting in the need for transfusion and
temporary mechanical ventilation. None of the patients
was admitted with the sequelae of infection: fever, chills,
productive sputum, or leukocytosis. All patients were con-
sidered to be “high-risk” surgical candidates because of
comorbidities or complications encountered during previ-
ous thoracotomies. The patients had hemoptysis for
between 10 days to 1 year before undergoing endovascu-
lar treatment. In at least two of the cases, the patients had
undergone protracted outpatient observations and
repeated diagnostic evaluations. In retrospect, these were
quite clearly suggestive of the diagnosis but, nonetheless,
failed to show an actual fistulous tract. Only when one
patient was admitted in respiratory failure with massive
active hemorrhage after several prior hospitalizations was
the diagnosis entertained. The patient’s condition was sta-
bilized, and then she was transferred to our institution for
treatment 12 months after her bleeding had begun.
Clearly, it may be difficult to diagnose ABF, and a high
index of suspicion should be entertained in any patients
with a previous thoracotomy and hemoptysis regardless of
the lack of evidence with radiographic investigation.
The four most significant diagnostic modalities used
for our cases were CT scanning, angiography, bron-
choscopy, and TEE (Table II). Although chest radiogra-
phy and CT scanning were usually the initial radiographic
studies, these findings were nonspecific. Pseudoaneurysm,
aortic anatomy abnormality, and lung parenchyma com-
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Fig 1. Angiograms show aortobronchial fistulas (A and B).
Arrows denote fistulas.
Fig 2. A, Intraoperative TEE of aortobronchial fistula in trans-
verse view. B, In longitudinal view, fistula is seen, and stent graft
is in position before deployment. AO, True aortic lumen; F,
extraluminal blood flow; G, graft; PSA, pseudoaneurysm.
A
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pression were all suggestive findings on each CT scan.
Angiography demonstrated a fistulous tract in at least two
patients (Fig 1). One patient had an irregular wall in the
area of the previous graft suggestive of fistula.
Bronchoscopy was performed multiple times in two
patients in an effort to find the cause of persistent hemo-
pytsis. The tests showed the presence of blood but failed
to reveal the source. Washings and culture specimens were
obtained during bronchoscopy for all patients, but none
showed any signs of infectious diseases. No patients were
previously treated for recurrent pneumonia. Intraoperative
TEE yielded the most consistently positive findings,
clearly confirming the presence of a fistulous tract because
it breached the aortic walls of all four patients (Fig 2,A).
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TEE not only demonstrated the presence of the fistula but
also permitted us to guide the device into accurate place-
ment (Fig 2,B).
Five devices were successfully deployed in the four
patients (Table III). Sizes of the devices were selected
according to measurements from CT scanning and
intravascular ultrasound scanning. Length of the device
was selected so that the proximal and distal graft anasto-
mosis could be excluded. Only one patient was limited by
femoral artery size for intravascular access and had to
undergo retroperitoneal exposure of the iliac artery with
subsequent conduit attachment for device delivery.
During deployment, TEE showed the abrupt termination
of flow into the pseudoaneurysm in all cases in real time.
Table I. Patient characteristics
Interval between last Interval between
Previous Presenting thoracic aneurysm surgery onset of symptoms
Patient Age/sex thoracic surgeries Comorbidities symptoms and onset of symptoms and treatment
1 69/F TAA repair (1974), 
CABG (1996) COPD, hypertension, CHF Hemoptysis 23 years 4 weeks
2 53/M TAA repair (1984), 
PSA repair (1989) Hypertension Hemoptysis 10 years 7 weeks
3 75/M Aortic valve replacement Hypertension, diabetes, Hemoptysis, 3 years 10 days
(1994), TAA repair atrial fibrillation, cardiomyopathy Dyspnea, 
(1997) hypoxia
4 75/F TAA repair (1996) Hypertension, COPD,  Hemoptysis 3 years 1 year
ulcerative colitis, CHF, steroid respiratory 
dependence, aortic insufficiency failure
TAA, Thoracic aortic aneurysm; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; PSA,
pseudoaneurysm.
Table II. Diagnostic results before treatment
Patient Chest CT scan Angiography Bronchoscopy Transesophageal echocardiography
1 Slight aortic dilation Fistula visualized; pseudoaneurysm Blood in left lower lobe Fistula tract visualized
2 6-cm pseudoaneurysm at the 
distal graft anastomosis Fistula suspected No blood Fistula tract and pseudoaneurysm 
visualized
3 6.8-cm pseudoaneurysm at the No fistula visualized Blood in left bronchus Fistula tract and pseudoaneurysm
distal graft anastomosis visualized
4 Small saccular pseudoaneurysm Fistula visualized; pseudoaneurysm Blood in both bronchi Fistula tract and pseudoaneurysm
at distal graft anastomosis visualized
Table III. Procedural results
Type of Size of Procedure Amount of 
Patient device device(s) Access time EBL (mL) contrast (mL) Follow-up Complications
1 Gianturco 34 mm × 10 cm Femoral artery 140 minutes 200 240 No recurrent None
Z stents and hemoptysis, 
polyester graft died 2 years after 
procedure of CHF
2 Excluder 28 mm × 7 cm Femoral artery 160 minutes 300 160 No recurrent None
hemoptysis at 1 year
3 Excluder 34 mm × 20 cm, Femoral artery 120 minutes 100 280 No recurrent None
40 mm × 10 cm hemoptysis at 
8 months
4 Excluder 34 mm × 20 cm Iliac artery 140 minutes 400 200 No recurrent None
hemoptysis at 
6 months
CHF, Congestive heart failure.
Deployment was accurate without device migration.
Postdeployment angiography confirmed graft apposition
(Fig 3,A). Average estimated blood loss was 250 mL, and
operative time was 140 minutes.
The patients were extubated within 24 hours and
transferred from the intensive care unit the next day.
Postoperative CT scanning confirmed accurate placement,
and there were no endoleaks (Fig 3,B). The patients were
usually ambulatory the day after surgery and were dis-
charged by the fourth postoperative day. None had
hemoptysis after stent graft placement. No patients had
episodes of pneumonia or stent graft infection. There were
no operative or postoperative complications. One patient
died of chronic congestive heart failure 2 years after
undergoing stent grafting. The rest of the patients con-
tinue to do well at follow-up after 6 months to 1 year and
are seen routinely during clinic visits. All have returned to
their normal activities of daily living.
DISCUSSION
Aortobronchial fistula is a rare complication of tho-
racic aortic surgery. Without prompt surgical treatment,
the natural history of the condition is lethal exsanguina-
tion. ABF has been reported after the surgical repair of
aortic aneurysms, coarctation, patent ductus arteriosus,
aortic dissection, valvular heart disease, and other thoracic
procedures, with aneurysm repair being the most common
culprit.1-3 The foreign body reaction to prosthetic graft
and suture, tracheobronchial compression necrosis, pul-
satile pressure erosion, and localized pulmonary infection
are all implicated in the pathophysiology of fistula forma-
tion.2 In the presence of an aortic graft, the fistula is asso-
ciated with a pseudoaneurysm at the anastomotic site—as
a result of atherosclerotic disease progression and weaken-
ing of the aortic wall. A break in the integrity of the aor-
tic wall results in pseudoaneurysm formation. ABF has
been reported from 3 weeks to 23 years after surgery. To
date, about 55 cases of postoperative ABF have been
reported in the literature. Perioperative mortality rates in
patients treated with traditional surgical repair have been
reported to be as high as 25% for those with ABF1,2,5 and
41% in those with pseudoaneurysm.10 Postoperative mor-
bidity in open surgical repair is substantial and includes
prolonged ventilation, pneumonia, multiple organ failure,
myocardial infarction, and paraplegia.4
The diagnosis of ABF should be given serious consider-
ation in any patient with hemoptysis after a thoracic aortic
operation. Such patients warrant immediate diagnostic
investigation; however, the actual fistula is often undetected
before operation. Chest radiography, CT scanning, angiog-
raphy, bronchoscopy, chest magnetic resonance imaging,
and TEE have all been used to diagnose the lesion, but each
has its individual limitations. Chest radiography findings are
nonspecific and may demonstrate aneurysm dilation in the
presence of pulmonary infiltrates. CT scanning may detect
a pseudoaneurysm, periaortic hematoma, and consolidation
of adjacent lung. Angiography rarely identifies the fistula.
However, it more readily demonstrates the presence of a
false aneurysm, ulceration, and aortic irregularities.
Bronchoscopy excludes other pulmonary causes of hemop-
tysis and may show the site of entrance of the fistula into the
pulmonary tract. However, bronchoscopy may accidentally
dislodge clot within the fistula, resulting in exsanguinating
hemorrhage and respiratory arrest.1,2,5 Magnetic resonance
imaging has also been used for diagnosis.6 In all of our
patients, intraoperative TEE demonstrated a breach of
blood flow from the aortic graft into a pseudoaneurysm and
the presence of the fistulous tract. Although others have
expounded the use of CT scanning, angiography, and bron-
choscopy in the diagnosis of the fistula, TEE was the most
reliable test for our patients.
Once the diagnosis is established, definitive treatment
of ABF should be expeditious. Open surgical repair is usu-
ally a formidable challenge. The traditional approach
involves thoracotomy, aortic cross-clamping, possible car-
diopulmonary bypass with concomitant anticoagulation,
aorta repair, graft replacement or bypass, and pulmonary
tissue dissection in the face of dense adhesions. The
patients are often deemed to be at high risk because of
their severe comorbidities and the debilitating nature of
their condition. The potential for hemodynamic instability
in a formal open procedure can be fatal.
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Fig 3. A, Angiogram shows adequate endoluminal stent graft
placement. B, CT scan of thoracic stent graft after procedure.
A
B
Several centers have published their experiences with
endoluminal repair of thoracic aortic aneurysms, pseudo-
aneurysms, dissections, and penetrating ulcers. Preliminary
results appear promising. Initial series have reported a 30-
day mortality rate of about 10% and an overall technical
success rate of more than 90%. The feasibility of this tech-
nique continues to be demonstrated in the intermediate
results.11-15 Moreover, experience with endovascular tech-
nologies is now yielding a safer procedure. The move to
“second-generation” self-expandable stents, familiarity
with techniques of accurate device placement, modification
in device support systems, and an understanding of the pit-
falls of problematic vascular access has diminished the
number of perioperative complications.12 The second-
generation devices, such as the Gore Excluder, are easier to
deploy, conform more easily to the aortic contour, and are
less likely to migrate during placement.
To date, four reports of endovascular repair of ABF in
five patients have been published. The cases involved the
stent graft closure of ABFs of pseudoaneurysms after aor-
tic coarctation repair, patent ductus arteriosus, aortic
surgery for Takayasu’s arteritis, and descending thoracic
aortic aneurysm replacement. All of these patients had
undergone multiple thoracic procedures and were diag-
nosed with varying degrees of hemoptysis. Each patient
was deemed to be at high surgical risk, and therefore
endovascular repair was attempted. A self-expanding stent
device covered with polyester graft material was deployed
in each case with technical success and no further bleeding.
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